ANKE BIO(SZ:300009) Ge Long Hui A P P·2025-10-21 00:06Core Viewpoint - The company announced promising results from its clinical trial of the innovative biological drug HuA21 in combination with trastuzumab and chemotherapy for treating HER2-positive advanced gastric/gastroesophageal junction adenocarcinoma [1] Group 1: Clinical Trial Results - The latest research findings were presented at the 2025 European Society for Medical Oncology (ESMO) annual meeting [1] - A total of 60 HER2-positive advanced gastric/gastroesophageal junction adenocarcinoma patients were enrolled in the study as of February 20, 2025 [1] - The objective response rate (ORR) for the HuA21 (30 mg/kg) group was 80.8%, while the ORR for the HuA21 (20 mg/kg) group was 76.7%, indicating strong anti-tumor activity [1] - There were no statistically significant differences in demographic and baseline characteristics between the two patient groups [1]